Posttraumatic stress disorder: Psychopathology, medical management, and dental implications

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 97, Issue 1, 2004, Pages 5-11

  Friedlander, Arthur H ^a,b,c   Friedlander, Ida K ^d   Marder, Stephen R ^a,e,f  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UCLA SCHOOL OF DENTISTRY   (United States)

^d W Valley/Los Angeles Co Dept H   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICARIES AGENT; SEDATIVE AGENT;

ALCOHOL ABUSE; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRINKING BEHAVIOR; EDUCATION; FEMALE; HUMAN; MALE; MENTAL DISEASE; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL WITHDRAWAL; REVIEW; SMOKING; TOBACCO DEPENDENCE; TOOTH DISEASE;

EID: 0346059460     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2003.09.004     Document Type: Article

References (107)

1. Diagnostic and statistical manual of mental disorders. 4th ed :1994;424-429 American Psychiatric Association, Washington, DC.
2. Yehuda R. Post-traumatic stress disorder. New Engl J Med. 346:2002;108-114.
3. Orr S.P., Metzger L.J., Pitman R.K. Psychophysiology of post-traumatic stress disorder. Psychiatr Clin North Am. 25:2002;271-293.
4. Solomon S.D., Davidson J.R.T. Trauma prevalence, impairment, service use, and cost . J Clin Psychiatry. 58:(Suppl):1993;5-11.
5. Young R.M., Lawford B.R., Noble E.P., Kann B., Wilkie A., Ritchie T., et al. Harmful drinking in military veterans with post-traumatic stress disorder association with the D2 dopamine receptor A1 allele . Alcohol Alcohol. 37:2002;451-456.
6. Jacobsen L.K., Southwick S.M., Kosten T.R. Substance use disorders in patients with posttraumatic stress disorder a review of the literature . Am J Psychiatry. 158:2001;1184-1190.
7. Pfefferbaum P., Vinekar S.S., Trautman R.P., Lensgraf S.J., Reddy C., Patel N., et al. The effect of loss and trauma on substance abuse behavior in individuals seeking support services after the 1995 Oklahoma City bombing. Ann Clin Psychiatry. 14:2002;89-95.
8. Chilcoat H.D., Breslau N. Post traumatic stress disorder and drug disorders testing causal pathways . Arch Gen Psychiatry. 55:1998;913-917.
9. Resnick H.S., Acierno R., Kilpatrick D.G. Health impact of interpersonal violence 2 medical and mental health outcomes . Behav Med. 23:1997;65-78.
10. Acierno R., Kilpatrick D.G., Resnick H.S., Saunders B.E., Best C.L. Violent assault, post-traumatic stress disorder, and depression risk factors for cigarette use among adult women . Behav Modif. 20:1996;363-384.
11. Hertzberg M.A., Moore S.D., Feldman M.E., Beckham J.C. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol. 21:2001;94-98.
12. Engel C.C., Liu X., McCarthy B.D., Miller R.F., Ursano R. Relationship of physical symptoms to posttraumatic stress disorder among veterans seeking care for Gulf War-related health concerns. Psychosom Med. 62:2000;739-745.
13. Calhoun P.S., Bosworth H.B., Grambow S.C., Dudley T.K., Bechham J.G. Medical service utilization by veterans seeking help for posttraumatic stress disorder. Am J Psychiatry. 159:2002;2081-2086.
14. Wagner A.W., Wolfe J., Rotnitsky A., Proctor S.P., Erickson D.J. An investigation of the impact of posttraumatic stress disorder on physical health. J Trauma Stress. 13:2000;41-55.
15. Kessler R.C., Sonnega A., Bromet E., Hughes M., Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 52:1995;1048-1060.
16. Foa E.B., Keane T.M., Friedman M.J. Guidelines for treatment of PTSD. J Trauma Stress. 13:2000;539-588.
17. Breslau N., Chilcoat H.D., Kessler R.C., Peterson E.L., Lucia V.C. Vulnerability to assaultive violence further specification of the sex difference in post-traumatic stress disorder . Psychol Med. 29:1999;813-821.
18. North C.S., Nixon S.J., Shariat S., Mallone S., McMillen J.C., Spitznagel E.L., et al. Psychiatric disorders among survivors of the Oklahoma City bombing. JAMA. 282:1999;755-762.
19. Schuster M.A., Stein B.D., Jaycox L., Collins R.L., Marshall G.N., Elliott M.N. A national survey of stress reactions after September 11, 2001, terrorist attack. N Engl J Med. 345:2001;1507-1512.
20. Radant A., Tsuang D., Peskind E.R., McFall M., Raskind W. Biological markers and diagnostic accuracy in the genetics of post-traumatic stress disorder. Pyschiatry Res. 102:2001;203-214.
21. Chantarujikapong S.I., Scherrer J.F., Xian H. A twin study of generalized anxiety disorder symptoms, panic disorder symptoms and post-traumatic stress disorder in men. Psychiatry Res. 103:2001;133-145.
22. Xian H., Chantarujikapong S.I., Scherrer J.F., Eisen S.A., Lyons M.J., Goldberg J., et al. Genetic and environmental influences on post-traumatic stress disorder, alcohol and drug dependence in twin pairs. Drug Alcohol Depend. 61:2000;95-102.
23. Stein M.B., Koverola C., Hanna C., Torchia M.G., McClarty B. Hippocampal volume in women victimized by childhood sexual abuse. Psychol Med. 27:1998;951-959.
24. Bremner J.D., Randall P., Scott T.M., Bronen R.A., Seibyl J.P., Southwick S.M., et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 152:1995;973-981.
25. Friedman M.J. Future pharmacotherapy for post-traumatic stress disorder prevention and treatment . Psychiatr Clin North Am. 25:2002;227-241.
26. Rauch S.L., van der Kolk B.A., Fisher R.E., Albert N.M., Orr S.P., Savage C.R., et al. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry. 53:1996;380-387.
27. Rauch S.L., Whalen P.J., Shin L.M., McInerney S.C., Macklin M.L., Lasko N.B., et al. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder a functional MRI study . Biol Psychiatry. 47:2000;769-776.
28. Ehlert U., Gaab J., Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders the role of the hypothalamus-pituitary-adrenal axis . Biol Psychiatry. 57:2001;141-152.
29. Shin L.M., McNally R.J., Kosslyn S.M., Thompson W.L., Rauch S.L., Alpert N.M., et al. Regional cerebral blood flow during script-driven imagery in childhood sexual abuse-related PTSD a PET investigation . Am J Psychiatry. 156:1999;575-584.
30. Golier J., Yehuda R. Neuropsychological processes in post-traumatic stress disorder. Psychiatr Clin North Am. 25:2002;295-315.
31. Grossman R., Buchsbaum M.S., Yehuda R. Neuroimaging studies in post-traumatic stress disorder. Psychiatry Clin North Am. 25:2002;317-340.
32. McFarlane A.C., Yehuda R., Clark C.R. Biologic models of traumatic memories and post-traumatic stress disorder the role of the neural network . Psychiatr Clin North Am. 25:2002;253-270.
33. Rabois D., Batten S.V., Keane T.M. Implications of the biologic findings for psychological treatments of post-traumatic stress disorder. Psychiatr Clin North Am. 25:2002;443-462.
34. Buckley T.C., Kaloupek D.G. A meta-analytic examination of basal cardiovascular activity in posttraumatic stress disorder. Psychosom Med. 63:2001;585-594.
35. Foa E.B., Meadows E.A. Psychosocial treatments for posttraumatic stress disorder a critical review . Ann Rev Psychology. 48:1997;449-480.
36. Marks I., Lovell K., Noshirvani H., Livanou M., Thrasher S. Treatment of post-traumatic stress disorder by exposure and/or cognitive restructuring a controlled study . Arch Gen Psychiatry. 55:1998;317-325.
37. Tarrier N., Sommerfied C., Pilgrim H., Humphreys L. Cognitive therapy or imaginal exposure in the treatment of post-traumatic stress disorder twelve-month follow-up . Br J Psychitry. 175:1999;571-575.
38. Marshall R.D., Schneier F.R., Fallon B.A., Knight C.B., Abbate L.A., Goetz D., et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol. 18:1998;10-18.
39. Marshall R.D., Cloitre M. Maximizing treatment outcome in PTSD by combining psychotherapy with pharmacotherapy. Curr Psychiatry Rep. 2:2000;335-340.
40. Schatzberg A.F. New indications for antidepressants. J Clin Psychiatry. 61:(Suppl 11):2000;9-17.
41. van der Kolk B.A. The psychobiology and psychopharmacology of PTSD. Hum Psychopharmacol Clin Exp. 16:2001;S49-S64.
42. Stein DJ, Seedat S, van der Linden GJ, Zungu-Dirway N. Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized control trials. Int Clin Psychopharmacol2000;Suppl 2:S31-9.
43. Sullivan G.M., Gorman J.M. Finding a home for post-traumatic stress disorder in biologic psychiatry is it a disorder of anxiety, mood, stress, or memory? Psychiatr Clin North Am. 25:2002;463-468.
44. Brady K.T., Pearlstein T., Asnis G.M., Baker D., Rothbaum B., Sikes C.R., et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder a randomized control trial . JAMA. 283:2000;1837-1844.
45. Marshall R.D., Beebe K.L., Oldham M., Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD a fixed dose, placebo-controlled study . Am J Psychiatry. 158:2001;1982-1988.
46. Edwards J.G., Anderson I. Systemic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 57:1999;507-533.
47. Spigset O. Adverse reactions to selective serotonin reuptake inhibitors reports from a spontaneous reporting system . Drug Saf. 20:1999;277-287.
48. Davis L.L., Nugent A.L., Murray J., Kramer G.L., Petty F. Nefazodone treatment for chronic posttraumatic stress disorder an open trial . J Clin Psychopharmacol. 20:2000;159-164.
49. Hildago R., Hertzberg M.A., Mellman T., Petty F., Tucker P., Weisler R., et al. Nefazodone in post-traumatic stress disorder results from six open-label trials . Int Clin Psychopharmacol. 14:1999;61-68.
50. Smajkic A., Weine S., Djuric-Bijedic Z., Boskailo E., Lewis J., Pavkovic I. Sertraline, paroxetine and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. J Trauma Stress. 14:2001;445-452.
51. Hamner M.B., Frueh B.C. Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. Int Clin Psychopharmacol. 13:1998;233-234.
52. The expert consensus guideline series treatment of posttraumatic stress disorder. The expert consensus panels for PTSD . J Clin Psychiatry. 60:(Suppl 16):1999;1-76.
53. Clark R.D., Canive J.M., Calais L.A., Qualls C.R., Tuason V.B. Divalproex in posttraumatic stress disorder an open label clinical trial . J Trauma Stress. 12:1999;395-401.
54. Iancu I., Rosen Y., Moshe K. Antiepileptic drugs in posttraumatic stress disorder. Clin Neuropharmacol. 25:2002;225-229.
55. Muller-Oerlinghausen B., Retzow A., Henn F.A., Giedke H., Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group . J Clin Psychopharmacol. 20:2000;195-203.
56. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., et al. A randomized placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 57:2000;481-489.
57. 57th ed. 2003; Medical Economics: Montvale (NJ).
58. McEvoy G.K. AHFS drug information 2003. 2003;American Society of Health- System Pharmacists, Bethesda (Md).
59. Davidson J.R., Weisler R.H., Malik M.L., Connor K.M. Treatment of posttraumatic stress disorder with nefazodone. Int Clin Psychopharmacol. 13:1998;111-113.
60. Friedlander A.H., Mills M.J., Wittlin B.J. Dental management considerations for the patient with post-traumatic stress disorder. Oral Surg Oral Med Oral Pathol. 63:1987;669-673.
61. Friedlander A.H., Kreinik-Friedlander I. Dento-facial pathology in patients with post-traumatic stress disorder (PTSD). Refuat Hashinayim. 7:1989;3-6.
62. Vitello M., Ciancio S.G., Ditursi G. Presence of dental abfraction on post traumatic stress disorder patients. J Dent Res. 80:(Spec Issue (AADR Abs)):2001;97. (abst# 494).
63. Patients with PTSD risk damaging teeth. J Dent Hyg. 75:2001;115.
64. Aghabeigi B., Feinmann C., Harris M. Prevalence of post-traumatic stress disorder in patients with chronic idiopathic facial pain. Br J Oral Maxillofac Surg. 30:1992;360-364.
65. Elter J.R., Beck J.D., Slade G.D., Offenbacher S. Etiologic models for incident periodontal attachment loss. J Clin Periodontol. 26:1999;113-123.
66. Monteiro da Silva A.M., Oakley D.A., Newman H.N., Nohl F.S., Lloyd H.M. Psychosocial factors and adult onset rapidly progressive periodontitis. J Clin Periodontol. 23:1996;789-794.
67. da Silva A.M., Newman H.N., Oakley D.A. Psychosocial factors in inflammatory periodontal disease a review . J Clin Periodontol. 22:1995;516-526.
68. Kurer J.R.B., Watts T.L., Weinman J., Gower D.B. Psychological mood of regular dental attenders in relation to oral hygiene behaviour and gingival health. J Clin Periodontol. 22:1995;52-55.
69. Moss M.E., Beck J.D., Kaplan B.H., Offenbacher S., Weintraub J., Koch G.G., et al. Exploratory case-control analysis of psychosocial factors and adult periodontitis. J Periodontol. 67:(Suppl 10):1996;1060-1069.
70. Schleifer S.J., Keller S.E., Bartlett J.A., Eckholdt H.M., Delaney B.R. Immunity in young adults with major depressive disorder. Am J Psychiatry. 153:1996;477-482.
71. Ahlberg J., Rantala M., Savolainen A., Suvinen T., Nissinen M., Sarma S., et al. Reported bruxism and stress experience. Community Dent Oral Epidemiol. 30:2002;405-408.
72. Macfarlane T.V., Gray R.J., Kincey J., Worthington H.V. Factors associated with the temporomandibular disorder, pain dysfunction syndrome (PDS) Manchester case-control study . Oral Diseases. 7:2001;321-330.
73. Ohayon M.M., Li K.K., Guilleminault C. Risk factors for sleep bruxism in the general population. Chest. 119:2001;53-61.
74. Gerber P.E., Lynd L.D. Selective serotonin reuptake inhibitor-induced movement disorder. Ann Pharmacother. 32:1998;692-698.
75. Brown E.S., Hong S.C. Antidepressant-induced bruxism successfully treated with gabapentin. J Am Dent Assoc. 130:1999;1467-1469.
76. Study shows link between antidepressants, bruxism. J Am Dent Assoc. 131:2000;297.
77. Bostwick J.M., Jaffee M.S. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry. 60:1999;857-860.
78. Amsterdam J.D., Settle R.G., Doty R.L., Abelman E., Winokur A. Taste and smell perception in depression. Biol Psychiatry. 22:1987;1481-1485.
79. Anttila S.S., Knuuttila M.L., Sakki T.K. Depressive symptoms favor abundant growth of salivary lactobacilli. Psychosomatic Med. 61:1999;508-512.
80. Wallin M.S., Rissanen A.M. Food and mood relationship between serotonin and affective disorders . Acta Psychiatr Scand. 377:(Supp):1994;36-40.
81. Christensen L., Somers S. Comparison of nutrient intake among depressed and nondepressed individuals. Int J Eating Disord. 20:1996;105-109.
82. Gallagher R.M., Marbach J.J., Raphael K.G., Dohrenwend B.P., Cloitre M. Is major depression comorbid with temporomandibular pain and dysfunction syndrome? A pilot study. Clin J Pain. 7:1991;219-225.
83. Korszun A., Hinderstein B., Wong M. Comorbidity of depression with chronic facial pain and temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 82:1996;496-500.
84. Gatchel R.J., Garofalo J.P., Ellis E., Holt C. Major psychological disorders in acute and chronic TMD an initial examination . J Am Dent Assoc. 127:1996;1365-1374.
85. Sternberg E.M., Young W.S., Bernardini R., Calogero A.E., Chrousos G.P., Gold P.W., et al. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA. 86:1989;4771-4775.
86. Marbach J.J. Medically unexplained chronic orofacial pain. Temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia. Med Clin North Am. 83:1999;691-710.
87. Bergdahl M., Bergdahl J. Burning mouth syndrome prevalence and associated factors . J Oral Pathol Med. 28:1999;350-354.
88. Drage L.A., Rogers R.S. 3rd. Clinical assessment and outcome in 70 patients with complaints of burning or sore mouth symptoms. Mayo Clin Proc. 74:1999;223-228.
89. Drage L.A., Rogers R.S. Clinical assessment and outcome in 70 patients with complaints of burning or sore mouth symptoms. Mayo Clin Proc. 74:(3):1999;223-228.
90. Mandel L., Hamele-Bena D. Alcoholic parotid sialadenosis. J Am Dent Assoc. 128:1997;1411-1415.
91. Mandel L., Kastin B. Alcoholic sialosis. NY State Dent J. 66:2000;22-24.
92. Schottenfeld R.S., Pantalon M.V. Assessment of the patient. Galanter M., Kleber H.D. Textbook of substance abuse treatment. 2nd ed. 1999;109-119 American Psychiatric Press Inc, Washington, DC.
93. Dreizen S. Dietary and nutritional counseling in the prevention and control of oral disease. Compend Contin Educ Dent. 10:1989;558-564.
94. McGarry G.W., Gatehouse S., Vernham G. Idiopathic epistaxis, haemostasis and alcohol. Clin Otolaryngol. 20:1995;174-177.
95. Rubin R., Rand R.L. Alcohol and platelet function. Alcohol Clin Exp Res. 18:1994;105-110.
96. Kato T., Thie N.M., Montplaisir J.Y., Lavigne G.J. Bruxism and orofacial movements during sleep. Dent Clin North Am. 45:2001;657-684.
97. Brackett W.W., Browning W.D., Ross J.A., Brackett M.G. Two-year clinical performance of a polyacid-modified resin composite and a resin-modified glass-ionomer restorative material. Operative Dent. 26:2001;12-16.
98. Callahan A.M., Marangel L.B., Ketter T.A. Evaluating the clinical significance of drug interactions a systematic approach . Harvard Rev Psychiatry. 4:1996;153-158.
99. Kittelson L. Substance abuse. Ciancio S.G. ADA guide to dental therapeutics. 2nd ed :2000;560 ADA Publishing, Chicago.
100. Yagiela J.A., Picozzi A. General mechanisms of drug interactions. Yagiela J.A., Neidle E.A., Dowd F.J. Pharmacology and therapeutics for dentistry. 4th ed :1998;61-68 Mosby, St Louis.
101. Rizack M.A. The medical letter handbook of adverse drug interactions. 1998;5-19 Medical Letter Inc, New Rochelle (NY).
102. Lieber C.S. Mechanisms of ethanol-drug-nutrition interactions. J Toxicol Clin Toxicol. 32:1994;631-681.
103. Miller W.R., Heather N. Treating addictive behaviors. 2nd ed : 1998;Plenum Press, New York.
104. Henderson-Martin B. No more surprises screening patients for alcohol abuse . Am J Nurs. 100:2000;26-32.
105. Dart R.C. The use and effect of analgesics in patients who regularly drink alcohol. Am J Manage Care. 7:(19 Supplement):2001;S597-S601.
106. Mason B.T. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res. 20:(7 Suppl):1996;10A-16A.
107. Haas D.A. Management of fear and anxiety. Yagiela J.A., Neidle E.A., Dowd F.J. Pharmacology and therapeutics for dentistry. 4th ed :1998;623-633 Mosby, St Louis.